Showing results (191-200 of 234) with videos related to

Sort By:
Pageof 24
Cancer|June 1, 2016
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesGevorg N Tamamyan, Hagop M Kantarjian, Jing Ning, et al.
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Blood Advances|September 25, 2024
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literatureCôme Bommier, Brian K Link, Brianna J Gysbers, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphomaChelsea C Pinnix, Grace L Smith, Sarah Milgrom, et al.
The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
Scientific Reports|February 6, 2019
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin LymphomaSarah A Milgrom, Hesham Elhalawani, Joonsang Lee, et al.
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Blood Advances|November 14, 2022
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCLHua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, et al.
Pageof 24